Researchers at The University of Texas MD Anderson Cancer Center have created a comprehensive single-cell map of the tumor ...

STUDIO CITY, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Study results from the randomized, prospective phase III ENDURANCE (E1A11) trial, designed and conducted by the ECOG-ACRIN Cancer Research Group ...

A new risk assessment score developed by researchers at Dana-Farber Cancer Institute, the Broad Institute of MIT and Harvard, and Massachusetts General Hospital reveals how multiple myeloma, a form of ...

For patients with standard-risk, newly diagnosed multiple myeloma, a phase III trial showed that maintenance therapy with ...

Multiple Myeloma," Cleveland Clinic hematologist Sandra Mazzoni, DO, and host John Mangels continue their conversation on ...

Data show that patients’ multiple myeloma still fails to progress if patients receive less-frequent Tecvayli. A reduced dosing schedule of Tecvayli (teclistamab) continued to slow the progression of ...

FDA has accepted Bristol Myers Squibb's New Drug Application for mezigdomide in combination with carfilzomib and ...

May 29 (Reuters) - Bristol Myers Squibb (BMY.N), opens new tab said on Friday that its experimental oral drug mezigdomide delayed disease progression in a late-stage trial of multiple myeloma patients ...

The U.S. Food and Drug Administration (FDA) approved on Thursday Johnson & Johnson’s (NYSE:JNJ) Darzalex Faspro (daratumumab and hyaluronidase-fihj) for a type of blood cancer. Darzalex Faspro is the ...

Multiple myeloma is a relatively uncommon cancer of plasma cells, where excessive proliferation of these malignant cells within the bone marrow leads to abnormal antibody production. The disease ...

The U.S. Food and Drug Administration (FDA) on Monday accepted the new drug application for Bristol Myers Squibb & Co.’s BMY ...